Shared search · Find who works on your own topic
Microbiote intestinal et réponse aux inhibiteurs de points de contrôle immunitaire
How to read this map and check its sources? Illustrated guide
From 120 papers on this topic published since 2021, kept out of the 372 most relevant results of our searches on OpenAlex. Relevance was checked for the 120 closest papers only.
This is a sample of the field, not a census: a broad topic has many more papers than a map reads. Narrow the topic or edit the searches to map one part of it well.
The 4 searches run on OpenAlex · An overview of the field
- gut microbiome checkpoint inhibitor response
- gut bacteria cancer immunotherapy mechanisms
- microbiome biomarkers immune checkpoint blockade
- fecal microbiota transplantation immunotherapy resistance
The landscape
Les approches mécanistiques et translationnelles se recouvrent largement, mais la première privilégie les interactions immunitaires et les métabolites dans l’ensemble des immunothérapies, tandis que la seconde se concentre sur leur exploitation clinique avec les inhibiteurs de points de contrôle. Les analyses de signatures cherchent des associations prédictives reproductibles entre cohortes, alors que les travaux sur les toxicités distinguent bénéfice antitumoral et événements indésirables immunitaires. Les études du carcinome hépatocellulaire ancrent ces questions dans l’axe intestin–foie, tandis que les travaux sur d’autres contextes tumoraux examinent notamment le traitement reçu, l’infection, le statut microsatellitaire ou la situation adjuvante.
People
Ordered by the papers of the map they sign, counting more those they sign first, last or as corresponding author. Author order says who did what in many fields, not who leads a team; it is not used in alphabetical author lists, nor after the first fifteen authors of a large collaboration.
-
Bertrand Routy
Signatures microbiennes et prédiction multicohorte · 2Modulation microbienne et translation clinique · 1
Their papers on the topic
- A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
-
Daniel J. Spakowicz
Toxicités immunitaires et facteurs microbiens · 2Signatures microbiennes et prédiction multicohorte · 1
Their papers on the topic
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
- The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
-
Nyelia F. Williams
Toxicités immunitaires et facteurs microbiens · 2Signatures microbiennes et prédiction multicohorte · 1
Their papers on the topic
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
-
Karla A. Lee
Signatures microbiennes et prédiction multicohorte · 3Modulation microbienne et translation clinique · 1
Their papers on the topic
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
-
Anqi Lin
Signatures microbiennes et prédiction multicohorte · 1Modulation microbienne et translation clinique · 1
-
Beatrice Casadei
Signatures microbiennes et prédiction multicohorte · 2
-
Fyza Y. Shaikh
Signatures microbiennes et prédiction multicohorte · 1Toxicités immunitaires et facteurs microbiens · 1
Their papers on the topic
- Comparison of baseline gut microbiome features between response subgroups of patients (pts) with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
-
Georgina Venetia Long
Modulation microbienne et translation clinique · 1Mécanismes immunitaires et métabolites microbiens · 1
-
Jie Hong
Toxicités immunitaires et facteurs microbiens · 1Mécanismes immunitaires et métabolites microbiens · 1
-
Jun Qing Yu
Modulation microbienne et translation clinique · 1Mécanismes immunitaires et métabolites microbiens · 1
-
Jun Yu
Mécanismes immunitaires et métabolites microbiens · 2
-
Lin Shen
Toxicités immunitaires et facteurs microbiens · 1Contextes tumoraux et réponse thérapeutique · 1
Their papers on the topic
-
Peng Luo
Modulation microbienne et translation clinique · 1Signatures microbiennes et prédiction multicohorte · 1
-
Pier Luigi Zinzani
Signatures microbiennes et prédiction multicohorte · 2
-
Rebecca C. Simpson
Modulation microbienne et translation clinique · 1Mécanismes immunitaires et métabolites microbiens · 1
-
Rinse Karel Weersma
Signatures microbiennes et prédiction multicohorte · 2
-
Ting Wei
Signatures microbiennes et prédiction multicohorte · 1Modulation microbienne et translation clinique · 1
-
Trevor D. Lawley
Signatures microbiennes et prédiction multicohorte · 2
-
Wisam Nabeel Ibrahim
Mécanismes immunitaires et métabolites microbiens · 2
-
Zhi Peng
Toxicités immunitaires et facteurs microbiens · 1Contextes tumoraux et réponse thérapeutique · 1
-
Amna Bibi
Toxicités immunitaires et facteurs microbiens · 2Signatures microbiennes et prédiction multicohorte · 1
Their papers on the topic
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
-
Harry Cheuk-Hay Lau
Mécanismes immunitaires et métabolites microbiens · 3
-
Xiaochen Yin
Contextes tumoraux et réponse thérapeutique · 2Toxicités immunitaires et facteurs microbiens · 1
Their papers on the topic
- Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer
- The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
-
Arielle Elkrief
Modulation microbienne et translation clinique · 1Signatures microbiennes et prédiction multicohorte · 1
-
Cynthia L. Sears
Signatures microbiennes et prédiction multicohorte · 1Toxicités immunitaires et facteurs microbiens · 1
Their papers on the topic
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
- Comparison of baseline gut microbiome features between response subgroups of patients (pts) with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
-
Francesca Romana Ponziani
Axe intestin–foie et carcinome hépatocellulaire · 2
-
Hailin Tang
Mécanismes immunitaires et métabolites microbiens · 2
-
Harry Sokol
Modulation microbienne et translation clinique · 2
-
Johannes R. Björk
Signatures microbiennes et prédiction multicohorte · 2
-
Lihaoyun Huang
Signatures microbiennes et prédiction multicohorte · 1Modulation microbienne et translation clinique · 1
Institutions
These are publication affiliations, not identified research teams. A national organization such as CNRS can include several independent laboratories.
Ordered by the papers one of their authors signs first, last or as corresponding author, then by their share of the papers: a paper signed by four institutions counts a quarter for each, so a large collaboration does not make each of its members look central.
-
Shanghai Jiao Tong University · CN
Mécanismes immunitaires et métabolites microbiens · 3Modulation microbienne et translation clinique · 2Toxicités immunitaires et facteurs microbiens · 1Signatures microbiennes et prédiction multicohorte · 1
Signing first, last or as corresponding author here: Jie Hong (2), Haoyan Chen (1), Jinkai Liu (1), Lijun Ning (1), Liliang Xia (1)
Matching papers with this affiliation
- The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
- Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events
- Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
-
Chinese University of Hong Kong · HK
Mécanismes immunitaires et métabolites microbiens · 3Modulation microbienne et translation clinique · 1
Signing first, last or as corresponding author here: Jun Qing Yu (2), Jun Yu (2), Harry Cheuk-Hay Lau (1), Mingxu Xie (1), Xing Kang (1)
Matching papers with this affiliation
- The gut microbiota in cancer immunity and immunotherapy
- Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
- Gut microbiota and immune alteration in cancer development: implication for immunotherapy
- Gut microbiome in modulating immune checkpoint inhibitors
-
The University of Texas MD Anderson Cancer Center · US
Signatures microbiennes et prédiction multicohorte · 1Modulation microbienne et translation clinique · 1Toxicités immunitaires et facteurs microbiens · 1Mécanismes immunitaires et métabolites microbiens · 1
Signing first, last or as corresponding author here: Jianjun J. Zhang (1), Sai‐Ching J. Yeung (1), Stephanie S. Watowich (1), Yinghong Wang (1)
Matching papers with this affiliation
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Microbiome influencers of checkpoint blockade–associated toxicity
- The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
-
Chinese University of Hong Kong, Shenzhen · CN
Mécanismes immunitaires et métabolites microbiens · 3
Signing first, last or as corresponding author here: Jun Yu (2), Harry Cheuk-Hay Lau (1), Jun Qing Yu (1), Mingxu Xie (1), Xing Kang (1)
-
Renji Hospital · CN
Mécanismes immunitaires et métabolites microbiens · 2Toxicités immunitaires et facteurs microbiens · 1
Signing first, last or as corresponding author here: Jie Hong (2), Haoyan Chen (1), Jinkai Liu (1), Lijun Ning (1), Mengwei Zhang (1)
Matching papers with this affiliation
-
Centre Hospitalier de l’Université de Montréal · CA
Signatures microbiennes et prédiction multicohorte · 2Modulation microbienne et translation clinique · 1
Signing first, last or as corresponding author here: Bertrand Routy (2), Arielle Elkrief (1), Cecilia Hes (1), Khoudia Diop (1)
Matching papers with this affiliation
- A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
-
Peking University Cancer Hospital · CN
Contextes tumoraux et réponse thérapeutique · 2Toxicités immunitaires et facteurs microbiens · 1
Signing first, last or as corresponding author here: Lin Shen (2), Zhi Peng (2), Jian Li (1), Keren Jia (1), Lin Shen (1)
Matching papers with this affiliation
- Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer
- The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
-
Chinese Academy of Medical Sciences & Peking Union Medical College · CN
Modulation microbienne et translation clinique · 2Mécanismes immunitaires et métabolites microbiens · 1Axe intestin–foie et carcinome hépatocellulaire · 1
Signing first, last or as corresponding author here: Chengpei Zhu (1), Haitao Zhao (1), Hanping Wang (1), Wenhui Yang (1), Xiaobo Yang (1)
Matching papers with this affiliation
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
- Critical role of the gut microbiota in immune responses and cancer immunotherapy
- Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
-
Sichuan University · CN
Mécanismes immunitaires et métabolites microbiens · 2Modulation microbienne et translation clinique · 1
Signing first, last or as corresponding author here: Hong Zhu (1), Jia Hu (1), Lin-Yong Zhao (1), Ling‐Ling Zhu (1), Wanting Lei (1)
-
West China Hospital of Sichuan University · CN
Mécanismes immunitaires et métabolites microbiens · 2Modulation microbienne et translation clinique · 1
Signing first, last or as corresponding author here: Hong Zhu (1), Jia Hu (1), Lin-Yong Zhao (1), Ling‐Ling Zhu (1), Wanting Lei (1)
-
University Medical Center Groningen · NL
Signatures microbiennes et prédiction multicohorte · 3
Signing first, last or as corresponding author here: Rinse Karel Weersma (2), Daoming Wang (1), Johannes R. Björk (1)
Matching papers with this affiliation
-
University of Groningen · NL
Signatures microbiennes et prédiction multicohorte · 3
Signing first, last or as corresponding author here: Rinse Karel Weersma (2), Daoming Wang (1), Johannes R. Björk (1)
Matching papers with this affiliation
-
Qatar University · QA
Mécanismes immunitaires et métabolites microbiens · 2
Signing first, last or as corresponding author here: Wisam Nabeel Ibrahim (2), Sawsan Sudqi Said (1)
-
Huazhong University of Science and Technology · CN
Signatures microbiennes et prédiction multicohorte · 1Modulation microbienne et translation clinique · 1
Signing first, last or as corresponding author here: Tian Xia (1), Xunhui Cai (1), Yuhang Xie (1)
-
Istituto di Ematologia di Bologna · IT
Signatures microbiennes et prédiction multicohorte · 2
Signing first, last or as corresponding author here: Beatrice Casadei (2), Pier Luigi Zinzani (2)
Approaches
The papers are grouped by the similarity of their titles and abstracts; an AI names each group from its papers. A paper is in one group only.
-
Mécanismes immunitaires et métabolites microbiens
Ces articles synthétisent les interactions du microbiote intestinal et de ses métabolites avec les cellules immunitaires et le microenvironnement tumoral, ainsi que leurs implications pour les biomarqueurs et la modulation des immunothérapies.
People: Harry Cheuk-Hay Lau, Jun Yu, Wisam Nabeel Ibrahim, Hailin Tang, Georgina Venetia Long, Jie Hong
Institutions: Shanghai Jiao Tong University, Chinese University of Hong Kong, Chinese University of Hong Kong, Shenzhen, Renji Hospital, Sichuan University
Its papers
- The Gut Microbiota–Immunity Axis in Colorectal Cancer: Implications for Immunotherapy and Clinical Translation
- Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications
- The relationship between gut microbiota and cancer immune response and immunotherapy
- Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization
- Gut Microbiota-Derived Metabolites in Cancer Immunotherapy: Mechanisms and Clinical Potential
- Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy
- The role of gut mycobiome in responses to cancer immunotherapy
- The microbiome role in modulating immune response — perspectives for cancer immunotherapy
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
- The gut microbiota in cancer immunity and immunotherapy
- Gut microbiota shapes cancer immunotherapy responses
- The Interplay Between the Gut Microbiome and Immunotherapy in Gastrointestinal Malignancies: Mechanisms, Clinical Implications, And Therapeutic Potential
- The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer
- Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
- Gut microbiome and tumor immunotherapy
- Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
- The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer
- Gut microbiota and cancer immunotherapy: mechanisms and modifications
- Role of Gut Microbe in Cancer Immunotherapy
- The role of the gut microbiota in tumor, immunity, and immunotherapy
- Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy
- Critical role of the gut microbiota in immune responses and cancer immunotherapy
- Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
- Microbiome bacterial influencers of host immunity and response to immunotherapy
- Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
- Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
- Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
- The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
- Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
- The influence of gut microbiota on immunotherapy for Colorectal Cancer
- Gut microbiota and immune alteration in cancer development: implication for immunotherapy
- Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
- Diet-gut microbial interactions influence cancer immunotherapy
- Emerging roles of the gut microbiota in cancer immunotherapy
- Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
- Implication of gut microbiome in immunotherapy for colorectal cancer
- Gut Microbiota and Immunotherapy
- Association of the gut microbiome with cancer immunotherapy
- Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
- Gut microbiome and its role in colorectal cancer
-
Signatures microbiennes et prédiction multicohorte
Ces travaux recherchent des caractéristiques microbiennes associées à la réponse aux inhibiteurs de points de contrôle par séquençage, analyses de cohortes, synthèses et modèles prédictifs, en examinant notamment leur reproductibilité entre cancers et populations.
People: Karla A. Lee, Bertrand Routy, Beatrice Casadei, Pier Luigi Zinzani, Rinse Karel Weersma, Trevor D. Lawley
Institutions: University Medical Center Groningen, University of Groningen, Centre Hospitalier de l’Université de Montréal, Istituto di Ematologia di Bologna, Shanghai Jiao Tong University
Its papers
- 562 Targeting the gut microbiome to modulate immune checkpoint inhibitor toxicity and efficacy: a randomized exploratory clinical trial in progress
- Gut Microbiome Signatures and Immune Checkpoint Inhibitor Response in Gastrointestinal Cancers: Reproducibility and Translational Readiness
- The Tumour Microbiome and Response to Immune Checkpoint Blockade: A Critical Appraisal of Compartment-Specific Evidence
- Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review
- Meta-analytic microbiome target discovery for immune checkpoint inhibitor response in advanced melanoma
- Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types
- Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer
- GUT MICROBIOME DETERMINANTS OF IMMUNE CHECKPOINT INHIBITOR RESPONSE IN CANCER
- Multi-Kingdom Gut Microbiome Interaction Characteristics Predict Immune Checkpoint Inhibitor Efficacy Across Pan-Cancer Cohorts
- The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
- 1523P Gut microbiome composition associates with clinical response to immune checkpoint inhibitor (ICI) therapy across multiple patient cohorts
- Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
- 1265 Associations of the gut microbiome with immune checkpoint inhibitor response across different cancer types and cohorts identified using random forest and language models
- Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
- Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
- A gut microbial signature for combination immune checkpoint blockade across cancer types
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
- Gut microbial structural variation associates with immune checkpoint inhibitor response
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
- Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
- Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy: A Pilot Study
- Abstract 650: A machine learning model accurately predicts response to immune checkpoint inhibitors in colorectal cancer using the gut microbiome
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
-
Modulation microbienne et translation clinique
Ces revues examinent les données mécanistiques et cliniques reliant le microbiote à l’efficacité et à la toxicité des inhibiteurs de points de contrôle, et discutent son utilisation comme biomarqueur et cible d’intervention thérapeutique.
People: Harry Sokol, Bertrand Routy, Anqi Lin, Georgina Venetia Long, Jun Qing Yu, Peng Luo
Institutions: Shanghai Jiao Tong University, Chinese Academy of Medical Sciences & Peking Union Medical College, Chinese University of Hong Kong, The University of Texas MD Anderson Cancer Center, Centre Hospitalier de l’Université de Montréal
Its papers
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut Microbiome Control of Tumor Immune Checkpoint Inhibitor Response: Mechanistic Insights and Clinical Translation
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review
- Gut Microbiome Modulation and Outcomes of Immune Checkpoint Inhibitors in Solid Tumors: A Secondary Qualitative Review
- A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy
- The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists
- Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- The gut microbiome and cancer response to immune checkpoint inhibitors
- Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors
- The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
- The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
- Author response for "Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study"
- Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses
- Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
- Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors
- Modulating the gut microbiome to improve immune checkpoint inhibitor response to cancer: current therapies and emerging methods
- Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
- Gut microbiome in modulating immune checkpoint inhibitors
- Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer
- The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
-
Toxicités immunitaires et facteurs microbiens
Ces études et synthèses analysent les liens entre le microbiote, les événements indésirables immunitaires et la réponse thérapeutique, en considérant aussi les médicaments susceptibles de modifier le microbiote et la transplantation fécale.
People: Daniel J. Spakowicz, Nyelia F. Williams, Amna Bibi, Fyza Y. Shaikh, Jie Hong, Lin Shen
Institutions: Shanghai Jiao Tong University, The University of Texas MD Anderson Cancer Center, Renji Hospital, Peking University Cancer Hospital
Its papers
- Comparison of baseline gut microbiome features between response subgroups of patients (pts) with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
- Gut microbiome and immune checkpoint inhibitor toxicity
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events
- Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Microbiome influencers of checkpoint blockade–associated toxicity
- The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
- Impact of gut-microbiome altering drugs and fecal microbiota transplant on the efficacy and toxicity of immune checkpoint inhibitors: A systematic review
-
Axe intestin–foie et carcinome hépatocellulaire
Ces travaux examinent, dans le carcinome hépatocellulaire, les liens entre microbiote intestinal, métabolites, interactions entre règnes microbiens et résultats des inhibiteurs de points de contrôle, à travers des cohortes prospectives et des revues centrées sur l’axe intestin–foie.
People: Francesca Romana Ponziani
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College
Its papers
- Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma
- Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
- Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
- Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
- Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
-
Contextes tumoraux et réponse thérapeutique
Ces articles étudient les associations du microbiote avec les résultats thérapeutiques dans des contextes particuliers : cancer gastrique selon le traitement, infection à Helicobacter pylori dans des cancers digestifs, statut microsatellitaire du cancer colorectal et survie sans récidive du mélanome sous traitement adjuvant.
People: Xiaochen Yin, Lin Shen, Zhi Peng
Institutions: Peking University Cancer Hospital
Its papers
- Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade
- Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer
- The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
- The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
Papers
- 562 Targeting the gut microbiome to modulate immune checkpoint inhibitor toxicity and efficacy: a randomized exploratory clinical trial in progress
- Gut Microbiome Signatures and Immune Checkpoint Inhibitor Response in Gastrointestinal Cancers: Reproducibility and Translational Readiness
- The Tumour Microbiome and Response to Immune Checkpoint Blockade: A Critical Appraisal of Compartment-Specific Evidence
- The Gut Microbiota–Immunity Axis in Colorectal Cancer: Implications for Immunotherapy and Clinical Translation
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut Microbiome Control of Tumor Immune Checkpoint Inhibitor Response: Mechanistic Insights and Clinical Translation
- Microbiome–Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma
- Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications
- Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review
- The relationship between gut microbiota and cancer immune response and immunotherapy
- Comparison of baseline gut microbiome features between response subgroups of patients (pts) with advanced melanoma undergoing immune checkpoint inhibitor (ICI) therapy.
- Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization
- Meta-analytic microbiome target discovery for immune checkpoint inhibitor response in advanced melanoma
- Gut Microbiome Modulation and Outcomes of Immune Checkpoint Inhibitors in Solid Tumors: A Secondary Qualitative Review
- Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP
- Gene-level gut microbiome signatures as predictive biomarkers for response to immune checkpoint inhibitors across multiple cancer types
- A “healthy gut state” as the key determinant of immune checkpoint inhibitor efficacy
- Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade
- Gut Microbiota Biomarkers in Patients with Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
- Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer
- Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer
- GUT MICROBIOME DETERMINANTS OF IMMUNE CHECKPOINT INHIBITOR RESPONSE IN CANCER
- Gut Microbiota-Derived Metabolites in Cancer Immunotherapy: Mechanisms and Clinical Potential
- Gut microbiota–derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy
- Multi-Kingdom Gut Microbiome Interaction Characteristics Predict Immune Checkpoint Inhibitor Efficacy Across Pan-Cancer Cohorts
- The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists
- The impact of gut microbiota modulation on responses to immune checkpoint inhibitors in cancer
- The role of gut mycobiome in responses to cancer immunotherapy
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
- 1523P Gut microbiome composition associates with clinical response to immune checkpoint inhibitor (ICI) therapy across multiple patient cohorts
- Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
- The microbiome role in modulating immune response — perspectives for cancer immunotherapy
- Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
- Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer
- The gut microbiota in cancer immunity and immunotherapy
- Gut microbiota shapes cancer immunotherapy responses
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
- The Interplay Between the Gut Microbiome and Immunotherapy in Gastrointestinal Malignancies: Mechanisms, Clinical Implications, And Therapeutic Potential
- Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors
- The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer
- Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
- Microbiota-centered interventions to boost immune checkpoint blockade therapies
- Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification
- Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
- The gut microbiome and cancer response to immune checkpoint inhibitors
- Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
- Gut microbiome and immune checkpoint inhibitor toxicity
- Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
- Gut microbiome and tumor immunotherapy
- Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors
- Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
- 1265 Associations of the gut microbiome with immune checkpoint inhibitor response across different cancer types and cohorts identified using random forest and language models
- The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
- The role of the gut microbiome in modulating immunotherapy efficacy in colorectal cancer
- Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
- The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect
- Gut microbiota and cancer immunotherapy: mechanisms and modifications
- Role of Gut Microbe in Cancer Immunotherapy
- Author response for "Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study"
- The role of the gut microbiota in tumor, immunity, and immunotherapy
- Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
- Gut microbiome ecological topology as next-generation biomarkers for cancer immunotherapy
- Critical role of the gut microbiota in immune responses and cancer immunotherapy
- Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
- Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
- Microbiome bacterial influencers of host immunity and response to immunotherapy
- Are tumor-associated carbohydrates the missing link between the gut microbiome and response to immune checkpoint inhibitor treatment in cancer?
- A gut microbial signature for combination immune checkpoint blockade across cancer types
- Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses
- Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
- Gut microbiome for predicting immune checkpoint blockade-associated adverse events
- Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
- TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
- Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
- Gut microbial structural variation associates with immune checkpoint inhibitor response
- The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
- The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
- Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
- The influence of gut microbiota on immunotherapy for Colorectal Cancer
- Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade
- Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
- Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
- Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Gut microbiota and immune alteration in cancer development: implication for immunotherapy
- The gut microbiome affects response of treatments in HER2‐negative advanced gastric cancer
- Effects of concomitant gut-microbiome altering medications on immune checkpoint inhibitors therapy: A retrospective study.
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
- Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF study
- De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
- Obesity, cancer, and response to immune checkpoint inhibitors: Could the gut microbiota be the mechanistic link?
- Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
- Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy: A Pilot Study
- Abstract 650: A machine learning model accurately predicts response to immune checkpoint inhibitors in colorectal cancer using the gut microbiome
- Diet-gut microbial interactions influence cancer immunotherapy
- The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
- Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
- Emerging roles of the gut microbiota in cancer immunotherapy
- Microbiome influencers of checkpoint blockade–associated toxicity
- Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors
- Modulating the gut microbiome to improve immune checkpoint inhibitor response to cancer: current therapies and emerging methods
- Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
- Research Progress on Effects of Gut Microbiome on Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
- Implication of gut microbiome in immunotherapy for colorectal cancer
- Gut microbiome in modulating immune checkpoint inhibitors
- Gut Microbiota and Immunotherapy
- Modeling the effect of gut microbiome on therapeutic efficacy of immune checkpoint inhibitors against cancer
- Abstract 3523: A Black Raspberry dietary intervention to modify the gut microbiome and improve the response to immune checkpoint inhibitors
- Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
- The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
- Association of the gut microbiome with cancer immunotherapy
- Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma
- Gut microbiome and its role in colorectal cancer
- Impact of gut-microbiome altering drugs and fecal microbiota transplant on the efficacy and toxicity of immune checkpoint inhibitors: A systematic review
- The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review
Use this map
Export: people (CSV) · institutions (CSV) · papers (CSV) · BibTeX · RIS (Zotero, Mendeley, EndNote)
From the paper metadata of OpenAlex, which can be incomplete (affiliations, homonyms). Check before contacting anyone.